Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Common Equity (2022 - 2025)

Envoy Medical's Common Equity history spans 4 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, Common Equity rose 58.69% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$7.7 million, up 58.69%, while the annual FY2024 figure was -$18.8 million, 960.92% down from the prior year.
  • Common Equity for Q3 2025 was -$7.7 million at Envoy Medical, up from -$29.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $4.8 million in Q3 2023 and bottomed at -$47.5 million in Q1 2023.
  • The 4-year median for Common Equity is -$24.2 million (2025), against an average of -$21.5 million.
  • The largest annual shift saw Common Equity skyrocketed 118.74% in 2023 before it plummeted 960.92% in 2024.
  • A 4-year view of Common Equity shows it stood at -$36.2 million in 2022, then surged by 95.09% to -$1.8 million in 2023, then tumbled by 960.92% to -$18.8 million in 2024, then soared by 59.34% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Common Equity are -$7.7 million (Q3 2025), -$29.9 million (Q2 2025), and -$24.2 million (Q1 2025).